LillyDirect
Eli Lilly's direct-to-patient platform launched in 2024, offering brand-name Zepbound (tirzepatide) and Mounjaro through an integrated prescribing and fulfillment experience. Partners with telehealth providers for consultations and ships medications directly from Lilly's supply chain, bypassing traditional pharmacy intermediaries. Offers a home delivery option with potential savings over retail pharmacy pricing.
Overview
- Consultation Model
- Hybrid
- Headquarters
- Indianapolis, IN
- Shipping
- 3-5 business days
- Lab Testing
- No
- Prescriber Info
- Consultations through partner telehealth platforms staffed by licensed physicians and nurse practitioners.
- Founded
- 2024
Pros
- Direct manufacturer supply chain — no compounding uncertainty
- Brand-name Zepbound and Mounjaro with manufacturer pricing
- Integrated prescribing and home delivery experience
- Potential savings over retail pharmacy pricing through Lilly coupons
Cons
- Limited to Lilly medications — no semaglutide or compounded options
- No peptide therapy beyond tirzepatide
- Requires insurance or out-of-pocket at brand-name prices
- Consultation through partner platforms, not Lilly's own clinicians
Pricing
| Medication | Dose | Price | Billing |
|---|---|---|---|
| tirzepatide | 2.5-15mg/week | $549 | monthly |